NCT02494999View on ClinicalTrials.gov

A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants

PHASE3CompletedINTERVENTIONAL
Enrollment

1,200

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

December 31, 2018

Study Completion Date

October 31, 2019

Conditions
Pneumonia
Interventions
BIOLOGICAL

13-valent pneumococcal conjugate vaccine

0.5ml vaccine produced by Beijing Minhai Biotechnology Co., Ltd.,three doses with 2 month interval, a booster dose 10 months after the first dose

BIOLOGICAL

Prevnar 13

0.5ml vaccine produced by Wyeth,three doses with 2 month interval, a booster dose 10 months after the first dose

Trial Locations (4)

222300

Huaiyin District Center for Diseases Control and Prevention, Huai'an

Unknown

Hongze District Center for Disease Control and Prevention, Huai'an

Lianshui County Center for Disease Control and Prevention, Huai'an

Guanyun County Center for Disease Control and Prevention, Lianyungang

Sponsors
All Listed Sponsors
collaborator

Beijing Minhai Biotechnology Co., Ltd

INDUSTRY

lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK